Clinical Trials at Corewell Health William Beaumont University Hospital
As of August 2026, 34 paid clinical trials are recruiting at Corewell Health William Beaumont University Hospital, located at Corewell Health William Beaumont University Hospital, 3601 W 13 Mile Rd, Royal Oak, MI 48073, phone (248) 898-5000 in Royal Oak, Michigan. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Advanced Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
34 clinical trials at Corewell Health William Beaumont University Hospital
·Clear filters·VE303 for Prevention of Recurrent Clostridioides Difficile Infection
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
Virtue® SAB in the Treatment of Coronary ISR Trial
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sacral Neuromodulation for Chronic Pelvic Pain
BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
Emsella Chair vs Sham for Male Sexual Dysfunction
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Quantitative MRI Assessment of Breast Cancer Therapy Response
Magnesium and Cramping
Common conditions studied in Royal Oak
- Breast Cancer (4 active studies)
- Acute Myeloid Leukemia (3 active studies)
- Advanced Breast Cancer (3 active studies)
- Atrial Fibrillation (3 active studies)
- Coronary Artery Disease (3 active studies)
- Malignant Solid Neoplasm (3 active studies)
Leading research sponsors in Royal Oak
- National Cancer Institute (NCI)
- Children's Oncology Group
- Corewell Health East
- NRG Oncology
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Royal Oak?
There are approximately 100 recruiting clinical trials in Royal Oak, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Royal Oak pay participants?
Most recruiting trials in Royal Oak compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Royal Oak?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Royal Oak?
The most common conditions under active study in Royal Oak include Breast Cancer (4), Acute Myeloid Leukemia (3), Advanced Breast Cancer (3), Atrial Fibrillation (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Royal Oak?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Royal Oak on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Royal Oak?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Royal Oak?
Recruiting research sites in Royal Oak include Corewell Health William Beaumont University Hospital, Corewell Health Children's, William Beaumont Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Royal Oak right now?
The largest active categories in Royal Oak are Cancer & tumors (47), Cardiovascular (9), Neurology & pain (5). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Corewell Health William Beaumont University Hospital?
Corewell Health William Beaumont University Hospital is located at Corewell Health William Beaumont University Hospital, 3601 W 13 Mile Rd, Royal Oak, MI 48073. Use the Google Maps link in the intro above to get directions.
How do I contact Corewell Health William Beaumont University Hospital?
You can reach Corewell Health William Beaumont University Hospital by phone at (248) 898-5000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.